Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 2,321–2,328 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Johnson & Johnson TAR-200 with Cetrelimab - (SunRISe-3) BCG-naïve High-risk Non-muscle Invasive Bladder Cancer Phase 3 Intravesical Oncology
Johnson & Johnson IMBRUVICA (ibrutinib) with Venetoclax - (SYMPATICO) Mantle cell lymphoma Phase 3 Ongoing Oral Oncology
Johnson & Johnson TREMFYA (guselkumab) - (GUIDE) Plaque psoriasis Phase 3 Subcutaneous Immunology: Anti-TNF
Johnson & Johnson Nipocalimab - (Vibrance-MG) Generalized myasthenia gravis Phase 2/3 Data Released Intravenous Neurology
Johnson & Johnson ARX788 (ACE-Gastric-02) Gastric cancer Phase 2/3 Intravenous Oncology
Johnson & Johnson Nipocalimab - (JASMINE) Adults living with systemic lupus erythematosus (SLE) Phase 2b Data Released Intravenous Immunology
Johnson & Johnson Posdinemab (JNJ-63733657) Alzheimer's disease (AD) Phase 2b Ongoing Intravenous Neurology
Johnson & Johnson TAR-200 with Cetrelimab - (SunRISe-4) High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Phase 2b Data Released Intravesical Oncology